Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CX-2029

Antibody-drug conjugate · Cytotoxic, directed at transferrin receptor 1 (CD71) (TFRC) · developed by CytomX Therapeutics

Phase 1/2 Most advanced trial (none active)
CTMX Developer
1 Registered trials

What is CX-2029?

CX-2029 is a probody-drug conjugate made of an anti-CD71 (transferrin receptor 1) antibody masked by a peptide that is cleaved by tumor-associated proteases, linked to the cytotoxic agent MMAE. After unmasking and internalization in CD71-expressing tumor cells, released MMAE binds tubulin and inhibits microtubule polymerization. It is studied in solid tumors, head and neck cancer, non-small cell lung cancer, diffuse large B-cell lymphoma and esophageal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
transferrin receptor 1 (CD71) (TFRC), tubulin (secondary target)
Mechanism
Cytotoxic, directed at transferrin receptor 1 (CD71) (TFRC)
Pathways
microtubule polymerization inhibition, G2/M phase arrest, apoptosis
Therapy area
Oncology
Developer
CytomX Therapeutics (CTMX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03543813 Phase 1/2 Solid Tumor, Adult Completed CTMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Large B Cell LymphomaEsophageal CancerHead and Neck CancerNon Small Cell Lung CancerSolid Tumor, Adult

Other drugs acting on TFRC

More from CytomX Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.

Follow CTMX, the company behind CX-2029

See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTMX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.